Radiopharmaceutical Theranostics in Primary Adrenal Malignancies: A Surgeon’s Perspective
Styliani Laskou·K Sapalidis·Petre Adrian Radu·Catalin Pirvu·Valeriu Şurlin·Christoforos Kosmıdis·Kyriakos Psarras·Ștelian Pantea·Victor Strâmbu·George Geropoulos
Radiopharmaceutical Theranostics defines the combination of molecularly targeted imaging and therapy in two consecutive phases. Targeted theranostic approaches are most established for the management of advanced prostate, thyroid and hepatocellular cancer, as well as neuroendocrine tumors (NETs). Adrenal malignancies present a complex challenge, requiring highly specialized management. The two primary entities addressed by targeted radiotheranostics—pheochromocytoma/paraganglioma (PPGL) and adre